Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.

被引：0
|
作者：
Santoni, Matteo
Porta, Camillo
Procopio, Giuseppe
Cerbone, Linda
Basso, Umberto
De Giorgi, Ugo
Rizzo, Mimma
Ortega, Cinzia
Massari, Francesco
Iacovelli, Roberto
di Lorenzo, Giuseppe
Milella, Michele
Sabbatini, Roberto
Atzori, Francesco
De Vivo, Rocco
Berardi, Rossana
Santini, Daniele
Cascinu, Stefano
机构：
[1] Polytech Univ Marche Reg, Azienda Osped Univ, Ospedali Riuniti Umberto I GM Lancisi & G Salesi, Ancona, Italy
[2] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] San Camillo & Forlanini Hosp, Rome, Italy
[5] Ist Oncol Veneto IOV IRCCS, Padua, Italy
[6] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[7] AORN Cardarelli, Naples, Italy
[8] Fdn Piemonte Oncol, Inst Canc Res & Treatment, Turin, Italy
[9] Univ Verona, Azienda Osped Univ Integrata, I-37100 Verona, Italy
[10] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[11] Reg Elena Natl Canc Inst, Rome, Italy
[12] Med Oncol Univ, Modena, Italy
[13] AOC Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy
[14] San Bortolo Hosp, Vicenza, Italy
[15] Univ Politecn Marche, AO Osped Riuniti, Clin Oncol Med, Ancona, Italy
[16] Univ Campus BioMed, Dept Med Oncol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Shitara, Kohei
    Matsuo, Keitaro
    Muro, Kei
    Doi, Toshihiko
    Ohtsu, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (08) : 1383 - 1389
  • [42] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Kohei Shitara
    Keitaro Matsuo
    Kei Muro
    Toshihiko Doi
    Atsushi Ohtsu
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1383 - 1389
  • [43] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Aglietta, M.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    Sternberg, C. N.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
  • [44] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
    Elena, V.
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Ortega, C.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    De Vincenzo, F.
    Procopio, G.
    BJU INTERNATIONAL, 2012, 110 : 5 - 5
  • [45] Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma
    Kucharz, Jakub
    Budnik, Monika
    Dumnicka, Paulina
    Pastuszczak, Maciej
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Popko, Katarzyna
    Wiechno, Pawel
    ADVANCES IN MEDICINE AND MEDICAL RESEARCH, 2019, 1133 : 35 - 40
  • [46] Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
    Zewei Zhang
    Chunxia Xie
    Tiantian Gao
    Yuxian Yang
    Yong Yang
    Lei Zhao
    BMC Cancer, 23
  • [47] RELATIONSHIP BETWEEN OVERALL RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) IN CLINICAL TRIALS OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
    Jen, M. H.
    Sonksen, M.
    Hess, L.
    Bian, F.
    VALUE IN HEALTH, 2023, 26 (06) : S44 - S44
  • [48] Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study
    Andre, T.
    Berton-Rigaud, D.
    Curigliano, G.
    Sabatier, R.
    Tinker, A. V.
    Oaknin, A.
    De Braud, F. G. M.
    Ellard, S.
    Arkenau, H-T.
    Trigo Perez, J. M.
    Brown, J.
    Jewell, A.
    Pikiel, J.
    Mirza, M. R.
    Duan, T.
    Antony, G.
    Zildjian, S.
    Zografos, E.
    Veneris, J.
    Banerjee, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S799 - S800
  • [49] Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
    Kucharz, Jakub
    Dumnicka, Paulina
    Giza, Agnieszka
    Demkow, Urszula
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    MEDICAL SCIENCE AND RESEARCH, 2019, 1153 : 31 - 45
  • [50] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710
12345